Added to YB: 2025-08-13
Pitch date: 2025-08-08
NOVO-B.CO [neutral]
Novo Nordisk A/S
-1.84%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 327.17
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 8/8/2025 - NOVOB – In-line results
NOVO-B.CO (earnings update): H1 sales +16% to DKK154.9bn, op profit +25% to DKK72.2bn. FY outlook downgraded to 8-14% CER sales growth (vs 16% H1) due to compounded GLP-1s, slower market growth, competition. Obesity sales +56%. Long-term structural growth potential remains, compounding enforcement could boost near-term. Attractive at 11.4x fwd earnings.
Read full article (1 min)